biotech / news / / Devdiscourse
Zydus Lifesciences is set to acquire Assertio Holdings, a US pharmaceutical firm.
Zydus Lifesciences will acquire Assertio Holdings for USD 166.4 million.
KEY POINTS
- The deal gives Zydus access to Assertio's commercial infrastructure in US oncology supportive care.
- The acquisition process involves a tender offer followed by a merger, pending standard closing conditions.
- The transaction is expected to close in the 2026-27 financial year, expanding Zydus's global oncology presence.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →